Review article · 2023 · Open access

GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach

Jingyue Wang, Quanwei Wang, Xinyu Yang, Wei Yang, Dong-Rui Li, Jingyu Jin, Hui-Cong Zhang, Xianfeng Zhang

Frontiers in Endocrinology, 14, 1085799 · Published 1 February 2023 · DOI 10.3389/fendo.2023.1085799

Open PDFView at the publisherCite this paper

In brief

“GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach” is a 2023 review article by Jingyue Wang and 7 co-authors, published in Frontiers in Endocrinology. OpenAlex counts 347 citations as of 21 November 2026, which puts it in the top 1% of works published in 2023 by citations. It is open access under a CC BY licence: the full text is free to read at Frontiers in Endocrinology.

Citations
347
Most cited in
2026 (119)
Field-weighted impact
8.70
References
145
Authors
8

Abstract

Obesity is a complex disease characterized by excessive fat accumulation which is caused by genetic, environmental and other factors. In recent years, there has been an increase in the morbidity, disability rate,and mortality due to obesity, making it great threat to people's health and lives, and increasing public health care expenses. Evidence from previous studies show that weight loss can significantly reduce the risk of obesity-related complications and chronic diseases. Diet control, moderate exercise, behavior modification programs, bariatric surgery and prescription drug treatment are the major interventions used to help people lose weight. Among them, anti-obesity drugs have high compliance rates and cause noticeable short-term effects in reducing obese levels. However, given the safety or effectiveness concerns of anti-obesity drugs, many of the currently used drugs have limited clinical use. Glucagon-like peptide-1 receptor (GLP-1R) agonists are a group of drugs that targets incretin hormone action, and its receptors are widely distributed in nerves, islets, heart, lung, skin, and other organs. Several animal experiments and clinical trials have demonstrated that GLP-1R agonists are more effective in treating or preventing obesity. Therefore, GLP-1R agonists are promising agents for the treatment of obese individuals. This review describes evidence from previous research on the effects of GLP-1R agonists on obesity. We anticipate that this review will generate data that will help biomedical researchers or clinical workers develop obesity treatments based on GLP-1R agonists.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Wang, J., Wang, Q., Yang, X., Yang, W., Li, D.-R., Jin, J., Zhang, H.-C., & Zhang, X. (2023). GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach. Frontiers in Endocrinology, 14, 1085799. https://doi.org/10.3389/fendo.2023.1085799

MLA 9

Wang, Jingyue, et al. “GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach.” Frontiers in Endocrinology, vol. 14, 2023, p. 1085799. https://doi.org/10.3389/fendo.2023.1085799.

Chicago

Wang, Jingyue, Quanwei Wang, Xinyu Yang, Wei Yang, Dong-Rui Li, Jingyu Jin, Hui-Cong Zhang, and Xianfeng Zhang. 2023. “GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach.” Frontiers in Endocrinology 14: 1085799. https://doi.org/10.3389/fendo.2023.1085799.

Harvard

Wang, J. et al. (2023) ‘GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach’, Frontiers in Endocrinology, 14, p. 1085799. doi:10.3389/fendo.2023.1085799.

IEEE

J. Wang et al., “GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach,” Frontiers in Endocrinology, vol. 14, p. 1085799, 2023, doi: 10.3389/fendo.2023.1085799.

BibTeX

@article{wang2023receptor,
  title     = {{GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach}},
  author    = {Wang, Jingyue and Wang, Quanwei and Yang, Xinyu and Yang, Wei and Li, Dong-Rui and Jin, Jingyu and Zhang, Hui-Cong and Zhang, Xianfeng},
  journal   = {Frontiers in Endocrinology},
  year      = {2023},
  volume    = {14},
  pages     = {1085799},
  doi       = {10.3389/fendo.2023.1085799},
  url       = {https://doi.org/10.3389/fendo.2023.1085799}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
20231717
2024102102
2025109109
2026119119

Its field-weighted citation impact is 8.70: it has been cited 8.70 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment

  • GLP-1 receptor agonists
  • obesity treatment
  • incretins
  • anti-obesity drugs
  • weight loss
  • obesity complications
  • obesity pharmacotherapy

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Wang, J., Wang, Q., Yang, X., Yang, W., Li, D.-R., Jin, J., Zhang, H.-C., & Zhang, X. (2023). GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach. Frontiers in Endocrinology, 14, 1085799. https://doi.org/10.3389/fendo.2023.1085799

How many times has this paper been cited?

347 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Frontiers in Endocrinology: sign in and open the PDF from this page.

Who wrote this paper?

Jingyue Wang, Quanwei Wang, Xinyu Yang, Wei Yang, Dong-Rui Li, Jingyu Jin, Hui-Cong Zhang, Xianfeng Zhang.

What is the DOI of this paper?

10.3389/fendo.2023.1085799, permanently at https://doi.org/10.3389/fendo.2023.1085799. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.